Cellular senescence enhances adaptive anticancer immunosurveillance

Ines Marin; Manuel Serrano; Federico Pietrocola

doi:10.1080/2162402X.2022.2154115

Cellular senescence enhances adaptive anticancer immunosurveillance

Oncoimmunology. 2022 Dec 15;12(1):2154115. doi: 10.1080/2162402X.2022.2154115. eCollection 2023.

Authors

Ines Marin¹, Manuel Serrano^{1

2}, Federico Pietrocola³

Affiliations

¹ Aging and Metabolism Programme, Institute for Research in Biomedicine (IRB), Barcelona Institute of Science and Technology, Barcelona 08028, Spain.
² Catalan Institution for Research and Advanced Studies, Barcelona 08010, Spain.
³ Department of Biosciences and Nutrition, Karolinska Institute, Huddinge 14157, Sweden.

Abstract

Cancer therapy often induces senescence in some cancer cells. Senescent cells, due to their profoundly altered biology, may conceivably interact with the adaptive immune system in novel ways that may boost cancer immunosurveillance, triggering the clearance of both senescent and non-senescent neoplastic cells. In this regard, we have recently reported that senescent cancer cells exhibit potent antigenicity and adjuvanticity and can elicit strong CD8⁺ T cell-dependent anticancer effects when used as vaccination agents.

Keywords: Aging; immunopeptidome; inflammation; interferon; vaccination.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cellular Senescence*
Humans
Immune System
Monitoring, Immunologic
Neoplasms* / therapy

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article.